AstraZeneca Biopharma President talks drug rebates, pricing

The Street

11 July 2019 - Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

The government's decision to drop its plan to cut drug rebates from government drug plans could be a negative factor for pharma, according to AstraZeneca Biopharmaceuticals President Ruud Dobber.

The Trump Administration announced it is no longer pursuing a proposal to eliminate drug rebates from government drug plans on Thursday morning after months of touting the plan, much to the relief of shareholders in PBM-tied stocks like UnitedHealth and CVS Health.

Read The Street article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Pricing , Fees and charges